Diovan is now indicated as a potentially life-saving therapy for the more than 750,000 people in the EU who are at risk of a recurrent heart attack or other serious outcomes, such as cardiovascular mortality, hospitalization for heart failure, resuscitated cardiac arrest or stroke. Diovan is also being evaluated by EU regulatory authorities for people with heart failure.
This new indication for Diovan is for the treatment of clinically stable patients with symptomatic heart failure or asymptomatic left ventricular systolic dysfunction after a recent myocardial infarction (heart attack).
The new indication is based on results from a study named VALIANT, which demonstrated that Diovan improved survival and reduced cardiovascular events in high-risk patients following a heart attack.
Diovan is the most prescribed ARB (angiotensin receptor blocker) globally and one of the fastest-growing high blood pressure drugs on the market today. It is available as a first-line treatment for high blood pressure in more than 90 countries and in more than 60 for the treatment of heart failure in patients who also take usual therapy including diuretics, digitalis and either beta blockers or ACE inhibitors.